Specialty Pharmacy

Study examines association between breast cancer survival and neighborhood-level measures such as socioeconomic status.

In addition to 2 FDA-approved options, several clinical trials are investigating other potential treatments for immunoglobulin A nephropathy.

In addition to offering convenience and ease of access, Sullivan said allowing patients to receive care at home empowers them and improves quality of life.

Biosimilars are also expanding rapidly, offering new opportunities for payers, patients, and providers.

Panelists at AXS23 conference agree that the patient’s voice is the most critical, whether it is related to drug manufacturing, delivery, or marketing.

Study shows eplontersen maintains a consistent and sustained treatment effect and reinforces its potential treating hereditary transthyretin-mediated amyloid polyneuropathy, which can lead to heart failure.

Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.

Although these programs are not the entire solution to rising pharmacy costs, Marsh said they are an important part of solving the problem.

The law directs federal spending toward funding the internal revenue service, improving taxpayer compliance, lowering health care needs, and reducing carbon emissions.

The system is considered effective at identifying residual breast cancer following surgical resection.

The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.

Naveen Mansukhani, BPharm, discussed skyrocketing prices for specialty drugs and what is driving those increases.

Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the biosimilars landscape and where biosimilars fall in the process of pharmacy and medical benefit adoption.

Balancing clinicians’ priorities with the needs of patients and their families is crucial to ensure access and adherence to medications.

Relative risk of cancer-related death differed according to age of diagnosis.

Pharmacists play key roles in navigating prior authorizations and other limits on utilization, as well as educating and listening to patients and caregivers.

Session at the 2023 Asembia Summit notes that pharmacists play a particularly important role in the large multidisciplinary care team needed for Rett syndrome management.

The willingness of biology labs to evolve has been essential to the incredible rise of biologic drugs.

The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.

The market for digital therapeutics products is expected to grow given increasing global access to smart technologies, their cost-effectiveness, and the need for patient-specific treatments.

Pharmacists were asked about their levels of burnout, drivers and symptoms of this burnout, and what steps their workplaces had taken to improve the issue.

While the demand for professionals adept in the ability to work with big data is at an all-time high, there remains a significant lack of skilled talent.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Annual Asembia summit features insights from key opinion leaders, networking events, and continuing education sessions for pharmacists, pharmacy staff and stakeholders.

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Omidubicel-onlv therapy aims to quicken the recovery of neutrophils and reduce the risk of infection in patients with cancer.

The Apothecary Shoppe in Utah knows patients by name, garners new business via word of mouth.

Although payers have become somewhat accustomed to the high cost of specialty drugs, the price tags for gene therapies are causing “sticker shock.”

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

These data support using this combination therapy as a new first-line treatment option in patients with previously untreated metastatic or unresectable BTC.